Comparative analysis of humoral immune response upon the three first vaccines applied in Argentina: IgG production and neutralizing capacity against SARS-CoV-2
Open Access
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Direct comparison of antibody responses to four SARS-CoV-2 vaccines in MongoliaCell Host & Microbe, 2021
- Mechanisms of SARS-CoV-2 entry into cellsNature Reviews Molecular Cell Biology, 2021
- Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single doseCell Reports Medicine, 2021
- WHO International Standard for anti-SARS-CoV-2 immunoglobulinThe Lancet, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in ArgentinaPLOS Pathogens, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from RussiaThe Lancet, 2020
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2Cell Host & Microbe, 2020
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2Science, 2020